Skip to main content

Efficacy and safety of sivelestat in sepsis-induced acute respiratory distress syndrome: an updated meta-analysis based on disease severity and treatment strategy subgroups

In brief

Sivelestat was linked to 45% lower odds of death in sepsis-related ARDS

In a meta-analysis of 10 studies with mortality data for 943 patients, deaths were less common with sivelestat, and randomized trials showed a similar association. The findings support further study of the drug, but sparse reporting and possible differences in other treatments limit confidence; evidence does not yet show which patients are most likely to benefit.

Journal
Frontiers in medicine (Q1)
Published
27 October 2026
Study design
Systematic review / meta-analysis of RCTs
Evidence level
Level 1, High (CEBM 1a)
Authors
Abduwupuer Haibier, Jiawei Ma, Yuanyuan Wang, Tong Wu
PMID
43011073
DOI
10.3389/fmed.2026.1986111

Why clinicians should know about it

Abstract

OBJECTIVE: Sivelestat sodium hydrate is a selective neutrophil elastase inhibitor that attenuates neutrophil-mediated alveolar-capillary injury and is used in some East Asian countries for acute lung injury/ARDS. We evaluated the efficacy and safety of sivelestat in sepsis-induced acute respiratory distress syndrome (ARDS) and explored whether disease severity, baseline mortality risk, and treatment background modify the mortality effect. METHODS: We searched PubMed/MEDLINE, Embase, Cochrane CENTRAL, Web of Science, CNKI, Wanfang, and ClinicalTrials.gov from database inception to August 27, 2026. Eligible studies were adult studies of sepsis-induced ARDS comparing a sivelestat-containing regimen with an otherwise comparable regimen without sivelestat. COVID-19-only cohorts, non-septic ARDS, mixed-etiology studies without a separable sepsis subgroup, and comparisons in which both groups received sivelestat were excluded. The primary outcome was all-cause mortality; secondary outcomes included P/F ratio, duration of mechanical ventilation, ICU length of stay, organ-function scores, inflammatory markers, and adverse events. Mortality was pooled as odds ratios (ORs) using a random-effects model with restricted maximum likelihood; Hartung-Knapp intervals were used for the primary and study-design analyses. This review was prospectively registered in PROSPERO. RESULTS: Fourteen studies were eligible for qualitative synthesis, and 10 studies (943 patients) provided extractable 2 × 2 mortality data. Deaths occurred in 73/431 patients receiving sivelestat and 125/512 controls. Sivelestat was associated with lower mortality (OR=0.55, 95% CI 0.36-0.84; I2 = 0%). The signal persisted in randomized trials (OR=0.37, 95% CI 0.16-0.86; I2 = 0%). Study-level point estimates appeared more favorable in cohorts with baseline P/F < 100 mmHg and control mortality >30%; however, interaction tests were not statistically significant and severity analyses were ecological. Leave-one-out analyses were stable. Egger testing did not detect significant small-study asymmetry (P = 0.197), although power was limited. Baseline-stratified treatment effects by IL-6, PCT, CRP, or neutrophil elastase were unavailable for quantitative effect-modification analyses. CONCLUSIONS: In an updated and etiologically strict evidence synthesis, sivelestat was associated with lower mortality in sepsis-induced ARDS, including in randomized trials. Severe hypoxemia and high baseline risk remain plausible enrichment factors, but current aggregate evidence is insufficient to support a validated phenotype-guided prescribing rule. Co-intervention reporting was sparse, and residual confounding by prone positioning, sedation, neuromuscular blockade, and steroid background cannot be excluded. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD420261541158.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.